Niklas Mattsson1, Philip S Insel2, Michael Donohue3, William Jagust4, Reisa Sperling5, Paul Aisen6, Michael W Weiner2. 1. Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden2Department of Radiology and Biomedical Imaging, University of California, San Francisco3Center for Imaging of Neur. 2. Department of Radiology and Biomedical Imaging, University of California, San Francisco3Center for Imaging of Neurodegenerative Diseases, Department of Veterans Affairs Medical Center, San Francisco, California. 3. Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla. 4. Helen Wills Neuroscience Institute and School of Public Health, University of California, Berkeley. 5. Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.
Abstract
IMPORTANCE: Alzheimer disease has a long preclinical stage characterized by β-amyloid (Aβ) accumulation without symptoms. Several trials focus on this stage and use biomarkers to include Aβ-positive participants, but an even earlier prevention of Aβ accumulation may be an effective treatment strategy. OBJECTIVE: To determine whether people who appear to be Aβ negative but are at high risk for Aβ positivity within the near future can be identified. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal biomarker cohort study involving 35 cognitively healthy individuals who underwent cerebrospinal fluid (CSF) sampling for up to 3 years during the study (October 24, 2005, to September 1, 2014). All participants had normal CSF Aβ42 levels at baseline. MAIN OUTCOMES AND MEASURES: Predictors of future Aβ positivity (levels of CSF Aβ42 declining below a previously validated cutoff level of 192 ng/L) tested by random forest models. Tested predictors included levels of protein in the CSF, hippocampal volume, genetics, demographics, and cognitive scores. RESULTS: The CSF Aβ42 levels declined in 11 participants, and the CSF became Aβ positive. The baseline CSF Aβ42 level was a strong predictor of future positivity (accuracy, 79% [95% CI, 70%-87%]). Ten of 11 decliners had baseline CSF Aβ42 levels in the lower tertile of the reference range (<225 ng/L), and 22 of 24 nondecliners had baseline CSF Aβ42 levels in the upper 2 tertiles (≥225 ng/L). A high CSF P-tau level was associated with decline (accuracy, 68%; 95% CI, 55%-81%). CONCLUSIONS AND RELEVANCE: Baseline CSF Aβ42 levels in the lower part of the reference range are strongly associated with future Aβ positivity. This finding can be used in trials on very early prevention of Alzheimer disease to identify people at high risk for Aβ accumulation as defined by low CSF Aβ42 levels.
IMPORTANCE: Alzheimer disease has a long preclinical stage characterized by β-amyloid (Aβ) accumulation without symptoms. Several trials focus on this stage and use biomarkers to include Aβ-positive participants, but an even earlier prevention of Aβ accumulation may be an effective treatment strategy. OBJECTIVE: To determine whether people who appear to be Aβ negative but are at high risk for Aβ positivity within the near future can be identified. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal biomarker cohort study involving 35 cognitively healthy individuals who underwent cerebrospinal fluid (CSF) sampling for up to 3 years during the study (October 24, 2005, to September 1, 2014). All participants had normal CSF Aβ42 levels at baseline. MAIN OUTCOMES AND MEASURES: Predictors of future Aβ positivity (levels of CSF Aβ42 declining below a previously validated cutoff level of 192 ng/L) tested by random forest models. Tested predictors included levels of protein in the CSF, hippocampal volume, genetics, demographics, and cognitive scores. RESULTS: The CSF Aβ42 levels declined in 11 participants, and the CSF became Aβ positive. The baseline CSF Aβ42 level was a strong predictor of future positivity (accuracy, 79% [95% CI, 70%-87%]). Ten of 11 decliners had baseline CSF Aβ42 levels in the lower tertile of the reference range (<225 ng/L), and 22 of 24 nondecliners had baseline CSF Aβ42 levels in the upper 2 tertiles (≥225 ng/L). A high CSF P-tau level was associated with decline (accuracy, 68%; 95% CI, 55%-81%). CONCLUSIONS AND RELEVANCE: Baseline CSF Aβ42 levels in the lower part of the reference range are strongly associated with future Aβ positivity. This finding can be used in trials on very early prevention of Alzheimer disease to identify people at high risk for Aβ accumulation as defined by low CSF Aβ42 levels.
Authors: Philip S Insel; Niklas Mattsson; R Scott Mackin; Michael Schöll; Rachel L Nosheny; Duygu Tosun; Michael C Donohue; Paul S Aisen; William J Jagust; Michael W Weiner Journal: Neurology Date: 2016-04-15 Impact factor: 9.910
Authors: Christine L Tardif; Gabriel A Devenyi; Robert S C Amaral; Sandra Pelleieux; Judes Poirier; Pedro Rosa-Neto; John Breitner; M Mallar Chakravarty Journal: Hum Brain Mapp Date: 2017-11-21 Impact factor: 5.038
Authors: Clifford R Jack; Josephine Barnes; Matt A Bernstein; Bret J Borowski; James Brewer; Shona Clegg; Anders M Dale; Owen Carmichael; Christopher Ching; Charles DeCarli; Rahul S Desikan; Christine Fennema-Notestine; Anders M Fjell; Evan Fletcher; Nick C Fox; Jeff Gunter; Boris A Gutman; Dominic Holland; Xue Hua; Philip Insel; Kejal Kantarci; Ron J Killiany; Gunnar Krueger; Kelvin K Leung; Scott Mackin; Pauline Maillard; Ian B Malone; Niklas Mattsson; Linda McEvoy; Marc Modat; Susanne Mueller; Rachel Nosheny; Sebastien Ourselin; Norbert Schuff; Matthew L Senjem; Alix Simonson; Paul M Thompson; Dan Rettmann; Prashanthi Vemuri; Kristine Walhovd; Yansong Zhao; Samantha Zuk; Michael Weiner Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Ju-Hee Kang; Magdalena Korecka; Michal J Figurski; Jon B Toledo; Kaj Blennow; Henrik Zetterberg; Teresa Waligorska; Magdalena Brylska; Leona Fields; Nirali Shah; Holly Soares; Robert A Dean; Hugo Vanderstichele; Ronald C Petersen; Paul S Aisen; Andrew J Saykin; Michael W Weiner; John Q Trojanowski; Leslie M Shaw Journal: Alzheimers Dement Date: 2015-07 Impact factor: 21.566
Authors: Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen Journal: Biol Psychiatry Date: 2020-01-07 Impact factor: 13.382
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Ivan Koychev; Nemanja Vaci; Murat Bilgel; Yang An; Graciela Terrera Muniz; Dean F Wong; John Gallacher; Abhay Mogekhar; Marilyn Albert; Susan M Resnick Journal: Alzheimers Dement (Amst) Date: 2020-03-22